The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Imnovid (previously Pomalidomide Celgene) pomalidomide Additional monitoring | Bristol-Myers Squibb Pharma EEIG | Multiple Myeloma | 🇪🇺 EU 2013-08-05 | Order → |
| Somatropin Biopartners somatropin | BioPartners GmbH | Growth | 🇪🇺 EU 2013-08-05 | Order → |
| Atosiban SUN atosiban Generic | Sun Pharmaceutical Industries Europe B.V. | Obstetric Labor, Premature | 🇪🇺 EU 2013-07-31 | Order → |
| Imvanex smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara) Exceptional circumstancesAdditional monitoring | Bavarian Nordic A/S | Smallpox Vaccine; Monkeypox virus | 🇪🇺 EU 2013-07-31 | Order → |
| Lojuxta lomitapide Exceptional circumstancesAdditional monitoring | Chiesi Farmaceutici SpA | Hypercholesterolemia | 🇪🇺 EU 2013-07-31 | Order → |
| Pheburane sodium phenylbutyrate | Eurocept International B. V. | Carbamoyl-Phosphate Synthase I Deficiency Disease | 🇪🇺 EU 2013-07-30 | Order → |
| Lonquex lipegfilgrastim | Teva B.V. | 🇪🇺 EU 2013-07-25 | Order → | |
| Erivedge vismodegib | Roche Registration GmbH | Carcinoma, Basal Cell | 🇪🇺 EU 2013-07-12 | Order → |
| Iclusig ponatinib Accelerated assessment | Incyte Biosciences Distribution B.V. | Leukemia, Myeloid; Leukemia, Lymphoid | 🇪🇺 EU 2013-07-01 | Order → |
| Imatinib Accord imatinib Generic | Accord Healthcare S.L.U. | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 🇪🇺 EU 2013-06-30 | Order → |
| Maci matrix-applied characterised autologous cultured chondrocytes ATMP | Vericel Denmark ApS | Fractures, Cartilage | 🇪🇺 EU 2013-06-27 | Order → |
| Nuedexta dextromethorphan hydrobromide;quinidine sulfate | Jenson Pharmaceutical Services Limited | Neurobehavioral Manifestations | 🇪🇺 EU 2013-06-24 | Order → |
| Stayveer bosentan monohydrate | Janssen-Cilag International NV | Hypertension, Pulmonary; Scleroderma, Systemic | 🇪🇺 EU 2013-06-24 | Order → |
| Capecitabine SUN capecitabine Generic | Sun Pharmaceutical Industries Europe B.V. | Stomach Neoplasms; Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms | 🇪🇺 EU 2013-06-21 | Order → |
| Spedra avanafil | Phoenix Labs Unlimited Company | Erectile Dysfunction | 🇪🇺 EU 2013-06-21 | Order → |
| Xtandi enzalutamide | Astellas Pharma Europe B.V. | Prostatic Neoplasms | 🇪🇺 EU 2013-06-21 | Order → |
| Memantine ratiopharm memantine Generic | Ratiopharm GmbH | Alzheimer Disease | 🇪🇺 EU 2013-06-12 | Order → |
| Stribild elvitegravir;cobicistat;emtricitabine;tenofovir disoproxil | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2013-05-24 | Order → |
| HyQvia human normal immunoglobulin | Baxalta Innovations GmbH | Immunologic Deficiency Syndromes; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 🇪🇺 EU 2013-05-16 | Order → |
| Voriconazole Accord voriconazole Generic | Accord Healthcare S.L.U. | Aspergillosis; Candidiasis; Mycoses | 🇪🇺 EU 2013-05-16 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.